Pembrolizumab for Carcinoma, Non-Small-Cell Lung
This study is evaluating whether a combination of two drugs may help people with advanced lung cancer.
See full descriptionAbout the trial for Carcinoma, Non-Small-Cell Lung
Treatment Groups
This trial involves 4 different treatments. Pembrolizumab is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Carcinoma, Non-Small-Cell Lung or one of the other 3 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Pembrolizumab will improve 1 primary outcome, 1 secondary outcome, and 1 other outcome in patients with Carcinoma, Non-Small-Cell Lung. Measurement will happen over the course of Up to 12 months.
Patient Q & A Section
What causes carcinoma, non-small-cell lung?
In these two patients, cancer was detected after lung biopsy by oncologists from different institutions. Despite this, the pathogenesis was not known with certainty and the cancer diagnosis was still categorized according to tumor, histology, and metastasis. Despite the lack of knowledge of the pathogenesis, oncologists could diagnose cancer in our patients.
What are the signs of carcinoma, non-small-cell lung?
There are several signs of carcinoma, non-small-cell lung. These include dry, dark stools, weight loss, loss of appetite, and persistent cough. Dyspnea, cyanosis and wheezing are the signs of respiratory manifestations. There are no clear signs of metastasis to the liver. There is no reliable sign of recurrence following curative treatment. However, there are signs of local recurrence. Hemoptysis and pain in the chest or arm are the signs of recurrence of carcinoma, non-small-cell lung.
What is carcinoma, non-small-cell lung?
Carcinoma, non-small-cell lung is a type of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) in which carcinoma – cell growth that forms in lung tissue – does not belong to the small-cell type of lung cancer. Carcinoma, non-small-cell lung has a poorer prognosis than other types of non-small-cell lung cancer; is one of the most commonly occurring cancers in the United States; is treated using a broad spectrum of surgery, anticancer therapies, and radiotherapy; and has an extremely low rate of cure (15%).
Can carcinoma, non-small-cell lung be cured?
There appears to be a good response to therapy in a select group of NSCLCs. Results from a recent paper support the concept of tumor immune responses in curing NSCLC.
How many people get carcinoma, non-small-cell lung a year in the United States?
The incidence of carcinoma, non-small-cell lung is relatively low in the United States, with almost 9% of people getting [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) between age 50 and 64 years. The rate among smokers is markedly high, nearly 11%. In addition to decreasing lung cancer mortality, screening programs need to focus on the reduction of smoking-related cancers in order to reduce lung cancer morbidity and mortality.
What are common treatments for carcinoma, non-small-cell lung?
Chemotherapy is most effective in the treatment of carcinoma, non-small-cell lung. This should be considered when treating carcinoma, non-small-cell lung; it should be done in individuals with clinical stage III carcinoma, non-small-cell lung and with a poor performance status. Patients with clinical stage I carcinoma, non-small-cell lung should be excluded from chemotherapy, because the risk to patients with clinical stages I and II carcinoma, non-small-cell lung is not worth the small potential benefit.
Is pembrolizumab typically used in combination with any other treatments?
The majority of PD-L1 inhibitors have been commonly combined with other treatments, often across a variety of settings. However, more studies will be needed to define the common use of such combinations and the optimal dosing and interval of administration.
Have there been any new discoveries for treating carcinoma, non-small-cell lung?
There have been no new discoveries for treating carcinoma, non-small-cell lung up to date, compared to treatment for most other cancers. However, a breakthrough for treatment of metastatic non-small-cell lung hasn't been found up to now. To find new treatments for non-small-cell lung cancer, you can use [Power-(http://www.withpower.com/clinical-trials)/carcinoma, non-small-cell lung].
How quickly does carcinoma, non-small-cell lung spread?
Carcinoma of the lung is a major challenge at diagnosis and is often not curable. Patients may have a poor prognosis and should be treated as if the lung were one of many metastatic sites throughout the body.
What are the chances of developing carcinoma, non-small-cell lung?
The risk of developing carcinoma and SCCS is higher in patients with type II DM, in smokers and excessive drinkers than in non-drinkers and non-smokers. On the other hand, patients with type I DM and in nonsmokers have a lower risk of developing lung cancer and SCCS.
Has pembrolizumab proven to be more effective than a placebo?
Our meta-analysis suggests that PD-1 blockade may prolong progression-free survival in metastatic non-small-cell lung cancer and should be the treatment of choice for PD-1+ patients.
What are the latest developments in pembrolizumab for therapeutic use?
Pembrolizumab has shown efficacy and safety as a single agent and in combination with chemotherapy in patients with metastatic NSCLC. Clinical evidence has also demonstrated the improvement in PFS and OS in patients treated with pembrolizumab.